West Pharmaceutical Services (WST) continues to draw investor attention after recent share price moves, with the stock last closing at $349.42. The company’s returns over the past year invite closer inspection of its current positioning.

Over the past year West Pharmaceutical Services has combined a 26.42% year to date share price return with a 42.37% total shareholder return. The recent 30 day share price return of 2.67% and 7 day return of 1.31% indicate momentum has cooled slightly after a stronger 90 day gain of 15.36%.

If you are comparing West Pharmaceutical Services with other health focused opportunities, it could be useful to see which companies show up in our healthcare AI stocks screener as fresh ideas for further research 44 healthcare AI stocks.

After a strong run and a recent pause, West Pharmaceutical Services now trades at $349.42 against an average analyst estimate of $404.73 and an internal fair value that screens slightly lower. So where does fair value truly sit in that spread?

Most Popular Narrative: 13.5% Undervalued

At $349.42, West Pharmaceutical Services screens below the most followed fair value estimate of about $404, which is built on detailed earnings and margin forecasts that analysts have refreshed through 2026.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The introduction of an automated line for HVP delivery devices later in 2025 to early 2026 is expected to improve margins by driving operational efficiencies and scale, enhancing net margins.

Want to see what happens when GLP 1 exposure, higher value components, and expanding margins all sit in the same model? The fair value hinges on a specific mix of revenue growth, rising profitability, and a future earnings multiple that analysts think the market can support. Curious which of those assumptions does the heaviest lifting in that $404 figure and how sensitive it is to small changes?

Result: Fair Value of $404 (UNDERVALUED)

However, the West Pharmaceutical Services story also carries real risks, including pressure from tariffs on costs and uncertainty around GLP 1 and high value component demand patterns.

Another View on West Pharmaceutical Services Valuation

The first fair value narrative paints West Pharmaceutical Services as about 13.5% undervalued at $349.42. On simple P/E math though, the picture looks less comfortable. WST trades on 43.5x earnings compared with 37.8x for the global Life Sciences industry and 31.1x for peers, while the fair ratio sits at 22.3x. That gap suggests investors today are paying a clear premium. The question is whether you think the GLP 1 and high value product story fully justifies it or still leaves enough margin of safety.

Next Steps

After weighing both the premium P/E and the fair value narratives around West Pharmaceutical Services, it makes sense to pressure test the numbers yourself and decide where you stand. If you want a faster way to see why some investors are optimistic, start with the 2 key rewards.

Looking for more investment ideas beyond West Pharmaceutical Services?

If West Pharmaceutical Services has sharpened your interest, do not stop here. A few minutes with fresh stock ideas today could shape your next move tomorrow.

• Spot potential bargains quickly by scanning companies that combine quality fundamentals with attractive pricing using the 50 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies that aim to offer robust yields in the 10 dividend fortresses.
• Prioritise resilience by focusing on companies that target lower risk profiles through the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.